Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:XLRN Acceleron Pharma (XLRN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Acceleron Pharma Stock (NASDAQ:XLRN) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Acceleron Pharma alerts:Sign Up Key Stats Today's Range$178.75▼$178.7550-Day Range$172.08▼$179.6852-Week Range$108.82▼$189.99VolumeN/AAverage Volume572,759 shsMarket Capitalization$10.93 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAcceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.Read More… Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Receive XLRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acceleron Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address XLRN Stock News HeadlinesAcceleron Fusion has raised $15M to take a stab at colder fusion, filing revealsOctober 5, 2024 | techcrunch.comAcceleron Fusion has raised $15M to take another stab at cold fusion, filing revealsOctober 1, 2024 | yahoo.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.November 5, 2024 | Insiders Exposed (Ad)ORBIMED CAPITAL GP II LLC's Net WorthFebruary 27, 2024 | benzinga.comXLRN Historical DataOctober 20, 2023 | investing.comBrexit Bargain Buys: 14 More Stocks Picked by Morgan StanleyApril 15, 2023 | thestreet.comAstellas Pharma IncMarch 17, 2023 | reuters.comAcceleron Corp Becomes a Digital Correspondent BankDecember 14, 2022 | finance.yahoo.comSee More Headlines XLRN Stock Analysis - Frequently Asked Questions How were Acceleron Pharma's earnings last quarter? Acceleron Pharma Inc. (NASDAQ:XLRN) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by $0.18. The firm's revenue for the quarter was up 51.6% on a year-over-year basis. What other stocks do shareholders of Acceleron Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA) and Vertex Pharmaceuticals (VRTX). Company Calendar Last Earnings11/04/2021Today11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:XLRN CUSIPN/A CIK1280600 Webwww.acceleronpharma.com Phone(617) 649-9200Fax617-649-9988Employees312Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-166,030,000.00 Net Margins-226.01% Pretax Margin-225.99% Return on Equity-32.11% Return on Assets-29.45% Debt Debt-to-Equity RatioN/A Current Ratio12.14 Quick Ratio12.14 Sales & Book Value Annual Sales$92.52 million Price / Sales118.15 Cash FlowN/A Price / Cash FlowN/A Book Value$11.74 per share Price / Book15.23Miscellaneous Outstanding Shares61,156,000Free Float60,116,000Market Cap$10.93 billion OptionableOptionable Beta0.13 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:XLRN) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredHow high could Bitcoin go?Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acceleron Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acceleron Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
